POLARIS INSIGHTS

Boston Scientific anticipates Q4 2026 organic revenue down 3% to down 1% and adjusted EPS $0. 77-$0. 79 amid cyber and EP/WATCHMAN pressure

The development centers on boston Scientific anticipates Q4 2026 organic revenue down 3% to down 1% and adjusted.

More from the Markets desk